Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120976 · ClinicalTrials.gov registry record · Phase 1
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252
A Phase 1 study, sponsored by Akros Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT02120976: Clinical Trial Phase 1 study, sponsored by Akros Pharma.
NCT02120976 is a Phase 1 study that was terminated before completion, run by Akros Pharma. The registered enrollment target is 85 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02120976, a Phase 1 study, was terminated before completion, sponsored by Akros Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and PK of single oral doses of JTT-252 and the effect of food on the PK of JTT-252 in healthy subjects, and to evaluate the safety, tolerability, PK and PD of single oral doses of JTT-252 in type 2 diabetes mellitus subjects.
Interventions
- DRUG JTT-252 or Placebo
- DRUG JTT-252
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Why NCT02120976 stopped before completion
NCT02120976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 2 interventions - of which JTT-252 or Placebo is the first listed.
NCT02120976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02120976 about?
NCT02120976 is a clinical study titled "Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252". The purpose of this study is to evaluate the safety, tolerability, and PK of single oral doses of JTT-252 and the effect of food on the PK of JTT-252 in healthy subjects, and to evaluate the safety, tolerability, PK and PD of single oral doses of JTT-252 in type 2 diabetes mellitus subjects.
What is the current status of trial NCT02120976?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2014-04. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02120976?
The interventions under investigation include: JTT-252 or Placebo (DRUG), JTT-252 (DRUG).
Who is sponsoring clinical trial NCT02120976?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02120976's enrollment target sits among peer trials
85 656th of 2000 higher than 1,342 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia